SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment
- Supplementary File 1:
ZIP-Document (ZIP, 11 KiB)
Drancourt, M.; Cortaredona, S.; Melenotte, C.; Amrane, S.; Eldin, C.; La Scola, B.; Parola, P.; Million, M.; Lagier, J.-C.; Raoult, D.; Colson, P. SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment. Viruses 2021, 13, 890. https://doi.org/10.3390/v13050890
Drancourt M, Cortaredona S, Melenotte C, Amrane S, Eldin C, La Scola B, Parola P, Million M, Lagier J-C, Raoult D, Colson P. SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment. Viruses. 2021; 13(5):890. https://doi.org/10.3390/v13050890
Chicago/Turabian StyleDrancourt, Michel, Sébastien Cortaredona, Cléa Melenotte, Sophie Amrane, Carole Eldin, Bernard La Scola, Philippe Parola, Matthieu Million, Jean-Christophe Lagier, Didier Raoult, and Philippe Colson. 2021. "SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment" Viruses 13, no. 5: 890. https://doi.org/10.3390/v13050890